{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:23:42Z","timestamp":1793838222073,"version":"4.6.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Scientific Fund of the Mayor of the City of Vienna","award":["22214"],"award-info":[{"award-number":["22214"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43207-2","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:26:43Z","timestamp":1773246403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line"],"prefix":"10.1038","volume":"16","author":[{"given":"Sandra","family":"Stickler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Therese","family":"Eggerstorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Rieche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryana","family":"Teufelsbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hohenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Weigl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"43207_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"43207_CR2","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1038\/emm.2014.99","volume":"47","author":"RK Kim","year":"2015","unstructured":"Kim, R. K. et al. Activation of KRAS promotes the mesenchymal features of basal-type breast cancer. Exp. Mol. Med. 47, e137 (2015).","journal-title":"Exp. Mol. Med."},{"key":"43207_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02586-2","author":"E Henriet","year":"2023","unstructured":"Henriet, E. et al. Triple-negative breast tumors contain heterogeneous cancer cells expressing distinct KRAS-dependent collective and disseminative invasion programs. Oncogene https:\/\/doi.org\/10.1038\/s41388-022-02586-2 (2023).","journal-title":"Oncogene"},{"key":"43207_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","author":"C Perou","year":"2000","unstructured":"Perou, C. et al. Molecular portraits of human breast tumours. Nature https:\/\/doi.org\/10.1038\/35021093 (2000).","journal-title":"Nature"},{"key":"43207_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.21.2492","author":"LA Carey","year":"2006","unstructured":"Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA https:\/\/doi.org\/10.1001\/jama.295.21.2492 (2006).","journal-title":"JAMA"},{"key":"43207_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041524","author":"J Lee","year":"2023","unstructured":"Lee, J. Current treatment landscape for early triple-negative breast cancer (TNBC). J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm12041524 (2023).","journal-title":"J. Clin. Med."},{"key":"43207_CR7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0286","author":"JM Balko","year":"2014","unstructured":"Balko, J. M. et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0286 (2014).","journal-title":"Cancer Discov"},{"key":"43207_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01341-0","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J. Hematol. Oncol. https:\/\/doi.org\/10.1186\/s13045-022-01341-0 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"43207_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4147","author":"C Liedtke","year":"2008","unstructured":"Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2007.14.4147 (2008).","journal-title":"J. Clin. Oncol."},{"key":"43207_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/nature10933","author":"SP Shah","year":"2012","unstructured":"Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature https:\/\/doi.org\/10.1038\/nature10933 (2012).","journal-title":"Nature"},{"key":"43207_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159135","author":"CK Anders","year":"2016","unstructured":"Anders, C. K., Abramson, V., Tan, T. & Dent, R. The evolution of triple-negative breast cancer: from biology to novel therapeutics. Am. Soc. Clin. Oncol. Educ. Book. https:\/\/doi.org\/10.1200\/EDBK_159135 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"43207_CR12","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino, P. et al. HER2-low breast cancer: pathological and clinical landscape. J. Clin. Oncol. 38, 1951\u20131962 (2020).","journal-title":"J. Clin. Oncol."},{"key":"43207_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2024.01.008","author":"M Keskinkilic","year":"2024","unstructured":"Keskinkilic, M. & Sacks, R. Antibody-drug conjugates in triple-negative breast cancer. Clin. Breast Cancer. https:\/\/doi.org\/10.1016\/j.clbc.2024.01.008 (2024).","journal-title":"Clin. Breast Cancer"},{"key":"43207_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231152842","author":"E Nicol\u00f2","year":"2023","unstructured":"Nicol\u00f2, E., Bielo, B., Curigliano, L., Tarantino, P. & G. & The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther. Adv. Med. Oncol. https:\/\/doi.org\/10.1177\/17588359231152842 (2023).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"43207_CR15","doi-asserted-by":"publisher","unstructured":"Ramadan, W. S. et al. Interplay between epigenetics, expression of estrogen receptor-\u03b1, HER2\/ERBB2 and sensitivity of triple-negative breast cancer cells to hormonal therapy. Cancers (Basel) (2018). https:\/\/doi.org\/10.3390\/cancers11010013","DOI":"10.3390\/cancers11010013"},{"key":"43207_CR16","first-page":"35","volume":"4","author":"K Subik","year":"2010","unstructured":"Subik, K. et al. The expression patterns of ER, PR, HER2, CK5\/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Basic Clin. Res). 4, 35\u201341 (2010).","journal-title":"Breast Cancer (Basic Clin. Res)"},{"key":"43207_CR17","doi-asserted-by":"publisher","DOI":"10.23812\/j.biol.regul.homeost.agents.20243803.151","author":"M Teufelsbauer","year":"2024","unstructured":"Teufelsbauer, M. et al. Activity of the KRAS G12D inhibitor MRTX1133 against the mutant KRAS triple-negative MDA-MB-231 breast cancer cell line. J. Biol. Regul. Homeost. Agents. https:\/\/doi.org\/10.23812\/j.biol.regul.homeost.agents.20243803.151 (2024).","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"43207_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01259-6","author":"J Li","year":"2020","unstructured":"Li, J. et al. Circular HER2 RNA positive triple-negative breast cancer is sensitive to pertuzumab. Mol. Cancer. https:\/\/doi.org\/10.1186\/s12943-020-01259-6 (2020).","journal-title":"Mol. Cancer"},{"key":"43207_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.csbj.2019.12.004","volume":"18","author":"T Pantsar","year":"2019","unstructured":"Pantsar, T. The current understanding of KRAS protein structure and dynamics. Comput. Struct. Biotechnol. J. 18, 189\u2013198 (2019).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"43207_CR20","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N Engl. J. Med."},{"key":"43207_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N Engl. J. Med."},{"key":"43207_CR22","doi-asserted-by":"publisher","first-page":"1013902","DOI":"10.3389\/fonc.2022.1013902","volume":"12","author":"SF Bannoura","year":"2022","unstructured":"Bannoura, S. F., Khan, H. Y. & Azmi, A. S. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? Front. Oncol. 12, 1013902 (2022).","journal-title":"Front. Oncol."},{"key":"43207_CR23","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor. J. Med. Chem. 65, 3123\u20133133 (2022).","journal-title":"J. Med. Chem."},{"key":"43207_CR24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41417-023-00669-0","volume":"30","author":"D Tang","year":"2023","unstructured":"Tang, D. & Kang, R. Glimmers of hope for targeting oncogenic KRAS-G12D. Cancer Gene Ther. 30, 391\u2013393 (2023).","journal-title":"Cancer Gene Ther."},{"key":"43207_CR25","unstructured":"United States Government National Library of Medicine clinical studies. Mar (2025). https:\/\/clinicaltrials.gov\/ (accessed 28."},{"key":"43207_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07205-6","author":"M Holderfield","year":"2024","unstructured":"Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature https:\/\/doi.org\/10.1038\/s41586-024-07205-6 (2024).","journal-title":"Nature"},{"key":"43207_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07379-z","author":"UN Wasko","year":"2024","unstructured":"Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature https:\/\/doi.org\/10.1038\/s41586-024-07379-z (2024).","journal-title":"Nature"},{"key":"43207_CR28","doi-asserted-by":"publisher","unstructured":"Del Re, M. et al. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget (2018). https:\/\/doi.org\/10.18632\/oncotarget.23553","DOI":"10.18632\/oncotarget.23553"},{"key":"43207_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01705-z","author":"ME Bahar","year":"2023","unstructured":"Bahar, M. E., Kim, H. J. & Kim, D. R. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal. Transduct. Target. Ther. https:\/\/doi.org\/10.1038\/s41392-023-01705-z (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"43207_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.02.029","author":"GY Liou","year":"2016","unstructured":"Liou, G. Y. et al. Mutant KRAS-induced mitochondrial oxidative stress in acinar cells upregulates EGFR signaling to drive formation of pancreatic precancerous lesions. Cell. Rep. https:\/\/doi.org\/10.1016\/j.celrep.2016.02.029 (2016).","journal-title":"Cell. Rep."},{"key":"43207_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/21541248.2016.1262935","author":"C Schneeweis","year":"2017","unstructured":"Schneeweis, C. et al. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis\u2014A connection to licensing nodes. Small GTPases. https:\/\/doi.org\/10.1080\/21541248.2016.1262935 (2017).","journal-title":"Small GTPases"},{"key":"43207_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/nrc969","author":"J Downward","year":"2003","unstructured":"Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. https:\/\/doi.org\/10.1038\/nrc969 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"43207_CR33","doi-asserted-by":"publisher","unstructured":"Luttrell, D. K. et al. Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc. Natl Acad. Sci. USA (1994). https:\/\/doi.org\/10.1073\/pnas.91.1.83","DOI":"10.1073\/pnas.91.1.83"},{"key":"43207_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080930","author":"SM Kwak","year":"2019","unstructured":"Kwak, S. M. et al. EGFR-c-Src-mediated HDAC3 phosphorylation exacerbates invasion of breast cancer cells. Cells https:\/\/doi.org\/10.3390\/cells8080930 (2019).","journal-title":"Cells"},{"key":"43207_CR35","first-page":"1696","volume":"43","author":"C Jacobs","year":"1983","unstructured":"Jacobs, C. & R\u00fcbsamen, H. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res. 43, 1696\u20131702 (1983).","journal-title":"Cancer Res."},{"key":"43207_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03691-4","author":"N Chaudhary","year":"2025","unstructured":"Chaudhary, N. et al. EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI. Cancer Cell. Int. https:\/\/doi.org\/10.1186\/s12935-025-03691-4 (2025).","journal-title":"Cancer Cell. Int."},{"key":"43207_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple-negative breast cancer: pitfalls and progress. NPJ Breast Cancer. https:\/\/doi.org\/10.1038\/s41523-022-00468-0 (2022).","journal-title":"NPJ Breast Cancer"},{"key":"43207_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796","author":"O Obidiro","year":"2023","unstructured":"Obidiro, O., Battogtokh, G. & Akala, E. O. Triple-negative breast cancer treatment options and limitations: future outlook. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics15071796 (2023).","journal-title":"Pharmaceutics"},{"key":"43207_CR39","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2020.106","author":"N Fultang","year":"2021","unstructured":"Fultang, N., Chakraborty, M. & Peethambaran, B. Regulation of cancer stem cells in triple-negative breast cancer. Cancer Drug Resist. https:\/\/doi.org\/10.20517\/cdr.2020.106 (2021).","journal-title":"Cancer Drug Resist."},{"key":"43207_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07403-w","author":"M Teufelsbauer","year":"2024","unstructured":"Teufelsbauer, M. et al. BET-directed PROTACs in triple-negative breast cancer cell lines MDA-MB-231 and MDA-MB-436. Breast Cancer Res. Treat. https:\/\/doi.org\/10.1007\/s10549-024-07403-w (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"43207_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02007-7","author":"J Hallin","year":"2022","unstructured":"Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-02007-7 (2022).","journal-title":"Nat. Med."},{"key":"43207_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-021-00739-6","author":"JH Luttman","year":"2021","unstructured":"Luttman, J. H., Colemon, A., Mayro, B. & Pendergast, A. M. Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade. Cell. Commun. Signal. https:\/\/doi.org\/10.1186\/s12964-021-00739-6 (2021).","journal-title":"Cell. Commun. Signal."},{"key":"43207_CR43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.trecan.2015.07.004","volume":"1","author":"J Wang","year":"2015","unstructured":"Wang, J. & Pendergast, A. M. The emerging role of ABL kinases in solid tumors. Trends Cancer. 1, 110\u2013123 (2015).","journal-title":"Trends Cancer"},{"key":"43207_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah, Y. et al. The chronic myelogenous leukemia-specific P210 protein is the product of the BCR\/abl hybrid gene. Science 233, 212\u2013214 (1986).","journal-title":"Science"},{"key":"43207_CR45","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/sj.onc.1210714","volume":"27","author":"D Srinivasan","year":"2008","unstructured":"Srinivasan, D., Sims, J. T. & Plattner, R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 27, 1095\u20131105 (2008).","journal-title":"Oncogene"},{"key":"43207_CR46","doi-asserted-by":"publisher","first-page":"e0118854","DOI":"10.1371\/journal.pone.0118854","volume":"10","author":"C Chevalier","year":"2015","unstructured":"Chevalier, C. et al. ABL tyrosine kinase inhibition: variable effects on the invasive properties of different triple-negative breast cancer cell lines. PLoS One. 10, e0118854 (2015).","journal-title":"PLoS One"},{"key":"43207_CR47","first-page":"1661","volume":"4","author":"M Beran","year":"1998","unstructured":"Beran, M. et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. 4, 1661 (1998).","journal-title":"Clin. Cancer Res."},{"key":"43207_CR48","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger, M., Buchdunger, E. & Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640\u20132653 (2005).","journal-title":"Blood"},{"key":"43207_CR49","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11899-015-0248-3","volume":"10","author":"CA Eide","year":"2015","unstructured":"Eide, C. A. & O\u2019Hare, T. Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. Curr. Hematol. Malig Rep. 10, 158\u2013166 (2015).","journal-title":"Curr. Hematol. Malig Rep."},{"key":"43207_CR50","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdn352","volume":"19","author":"M Cristofanilli","year":"2008","unstructured":"Cristofanilli, M. et al. Imatinib mesylate (GleevecR) in advanced breast cancer expressing C-Kit or PDGFR-\u03b2: clinical activity and biological correlations. Ann. Oncol. 19, 1713\u20131719 (2008).","journal-title":"Ann. Oncol."},{"key":"43207_CR51","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13643","author":"S Bieerkehazhi","year":"2017","unstructured":"Bieerkehazhi, S. et al. Novel Src\/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src\/Abl signaling. Oncotarget https:\/\/doi.org\/10.18632\/oncotarget.13643 (2017).","journal-title":"Oncotarget"},{"key":"43207_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.18.638898","author":"A Colemon","year":"2025","unstructured":"Colemon, A., Prioleau, T., Rouse, C. & Pendergast, A. M. ABL kinases modulate EZH2 phosphorylation and signaling in metastatic triple-negative breast cancer. bioRxiv https:\/\/doi.org\/10.1101\/2025.02.18.638898 (2025).","journal-title":"bioRxiv"},{"key":"43207_CR53","doi-asserted-by":"publisher","unstructured":"Teufelsbauer, M. et al. Activity of the KRAS G12D Inhibitor MRTX1133 against the Mutant KRAS Triple-Negative MDA-MB-231 Breast Cancer Cell Line. J. Bio Regul. Homoest Agents. 38 https:\/\/doi.org\/10.23812\/j.biol.regul.homeost.agents.20243803.151 (2024).","DOI":"10.23812\/j.biol.regul.homeost.agents.20243803.151"},{"key":"43207_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg9652","author":"CJ Schulze","year":"2023","unstructured":"Schulze, C. J. et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science https:\/\/doi.org\/10.1126\/science.adg9652 (2023).","journal-title":"Science"},{"key":"43207_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00914-5","author":"AD Cox","year":"2025","unstructured":"Cox, A. D. & Der, C. J. Drugging mutant KRAS by disrupting binding to effectors and GTP. Nat. Cancer. https:\/\/doi.org\/10.1038\/s43018-025-00914-5 (2025).","journal-title":"Nat. Cancer"},{"key":"43207_CR56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0092-8674(86)90495-2","volume":"44","author":"CJ Der","year":"1986","unstructured":"Der, C. J., Finkel, T. & Cooper, G. M. Biological properties of the K-ras oncogene. Cell 44, 167\u2013175 (1986).","journal-title":"Cell"},{"key":"43207_CR57","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41586-024-08283-2","volume":"637","author":"A Cuevas-Navarro","year":"2025","unstructured":"Cuevas-Navarro, A. et al. Structure-guided development of a dual inhibitor of SHP2 and MEK for RAS-driven cancers. Nature 637, 224\u2013229 (2025).","journal-title":"Nature"},{"key":"43207_CR58","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10549-024-07403-w","volume":"208","author":"M Teufelsbauer","year":"2024","unstructured":"Teufelsbauer, M. et al. BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436. Breast Cancer Res. Treat. 208, 89\u2013101. https:\/\/doi.org\/10.1007\/s10549-024-07403-w (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"43207_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.005","author":"HM Kantarjian","year":"2024","unstructured":"Kantarjian, H. M. et al. A review of the therapeutic role of bosutinib in chronic myeloid leukemia. Clin. Lymphoma Myeloma Leuk. https:\/\/doi.org\/10.1016\/j.clml.2024.01.005 (2024).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"43207_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq4274","author":"X Song","year":"2024","unstructured":"Song, X. et al. SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.adq4274 (2024).","journal-title":"Sci. Adv."},{"key":"43207_CR61","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks, A. G. & Winer, E. P. Breast cancer treatment: a review. JAMA 321, 288\u2013300 (2019).","journal-title":"JAMA"},{"key":"43207_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0055-9","author":"MN Dickler","year":"2009","unstructured":"Dickler, M. N. et al. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res. Treat. https:\/\/doi.org\/10.1007\/s10549-008-0055-9 (2009).","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43207-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43207-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43207-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:34:32Z","timestamp":1776897272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43207-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43207"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43207-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13170"}}